# Referral patterns in the CKD.QLD Registry: a call for revisiting the definition of late referral

**Clyson Mutatiri[1,2]\*, Angela Ratsch [3,4], Matthew McGrail[5], Sree Krishna Venuthurupalli [6,7] and Srinivas Kondalsamy- Chennakesavan[8,9]**

[1]Renal Medicine, Bundaberg Base Hospital, Wide Bay Hospital and Health Service, 271 Bourbong St, Bundaberg Central QLD 4670, Australia; Email: clyson.mutatiri@health.qld.gov.au, Ph: +61 7 41502222, Fax: +61 41502449

[2]Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Bundaberg, Queensland, Australia.

[3]Research Services, Wide Bay Hospital and Health Service, Hervey Bay, Queensland, Australia

[4]Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Hervey Bay, Queensland, Australia

[5] Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Rockhampton, Queensland, Australia

[6] Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, Ipswich, Queensland, Australia

[7]Kidney Service, Department of Medicine, West Moreton Hospital and Health Service, Ipswich, Queensland, Australia

[8]Rural Clinical School, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Toowoomba, Queensland, Australia

[9] School of Health and Medical Sciences, University of Southern Queensland, Toowoomba, Queensland, Australia

**\*Corresponding author**

**Key words:** Chronic kidney disease, late referral, estimated glomerular filtration rate, urine albumin-to-creatinine ratio, Kidney Health Australia, kidney failure risk equation

# Abstract

## Background

The rising burden of chronic kidney disease (CKD) requires reinforcing of the current mechanisms for early detection and intervention. Although 'timely' referral to a specialist nephrology service plays a crucial role for many patients in ensuring improved outcomes, the lack of widely accepted definitions of timely (and by implication, early and late) referral may limit such outcomes.

## Study aim

To evaluate referral patterns among CKD.QLD Registry participants, focusing on the timing and appropriateness of referrals and their association with clinical outcomes.

## Methods

We conducted a retrospective cohort study of adults (≥18 years) enrolled in the CKD.QLD Registry from seven public nephrology clinics between May 2011 and June 2018. Participants were followed until kidney replacement therapy (KRT), death, or study closure. All CKD stages were included to assess demographic and clinical characteristics at referral and associated outcomes. Late referral was defined as initiation of KRT within 12 months of the first nephrology visit among those who progressed to KRT.

## Results

Among 3,775 participants (median age 65 years; 54.8% male; 8.7% Indigenous), hypertension (77.5%) and type 2 diabetes (44.9%) were the most common comorbidities. ESKD developed in 775 (20.5%) participants; 513 (66.2%) received KRT. Overall, 722 (19.1%) died, including 124 (17.2%) after starting KRT. Late referral occurred in 60 (11.7%) KRT participants, with

47  15 (25%) deaths, 3 within 12 months of KRT initiation. Most KRT patients (77.4%) and deaths

48  (65.5%) were in the high-comorbidity group; among KRT-related deaths, 101 (81.5%) were

49  high-comorbidity, and 351 (88.4%) were referred early.

## Conclusion

51  Late referral rates were lower than previously reported. Comorbidity burden, rather than

52  referral timing, was the stronger predictor of mortality. These findings highlight the need for a

53  standardized definition of late referral that incorporates risk stratification.

# Introduction

Chronic kidney disease (CKD) is a globally recognised contributor to increasing mortality and

morbidity, with an estimated worldwide prevalence of 13.4% [1]. The burden of CKD is

disproportionately borne by low-income countries and socio-economically disadvantaged

populations [2]. With increasing life expectancy, coupled with increasing prevalence of key

risk factors such as diabetes mellitus (DM) and hypertension, CKD has emerged as a critical

public health concern and drain on resources for health systems globally [3]. Early

identification and intervention are crucial for slowing the progression of CKD and improving

patient outcomes[4].

Early-stage CKD is predominately managed within primary care settings [5]. However, a

subset of these patients will ultimately require referral to nephrology clinics for specialist input,

particularly as their disease advances or if they develop complications [6]. Traditionally, the

referral of individuals with CKD from primary care to specialist nephrology services has been

guided by established protocols, such as those outlined by international bodies including

Kidney Disease: Improving Global Outcomes (KDIGO) [7], Kidney Health Australia (KHA)

[8], and other globally recognised guidelines. The timing of referral has historically been

considered a critical factor influencing outcomes, with the evidence demonstrating that earlier

referral allows for better preparation for kidney replacement therapy (KRT), optimised

management of comorbidities, and improved survival [9]. Late referral generally refers to

patients who had commenced KRT such as dialysis or kidney transplantation within a short

period (ranging from 1 to 12 months) following their initial nephrology clinic visit [10]. While

there is no universally agreed-upon timeframe, this operational time-based definition is widely

utilised in clinical studies [11].

Multiple studies have reported that late referral is associated with worse clinical outcomes,

including higher mortality rates, increased rates of hospitalisation, and poorer quality of life

[12, 13]. These adverse outcomes have been attributed to insufficient pre-dialysis education,

suboptimal management of anaemia, mineral bone disorder, and delayed preparation for

vascular access or transplantation [9]. However, the landscape of CKD management has

evolved considerably in recent years. Advances in the understanding of CKD pathophysiology,

the introduction of a working system based on estimated glomerular filtration rate (eGFR) and

albuminuria, and the recognition of albuminuria as an important marker for early detection and

risk stratification have all contributed to improved care [14, 15]. The emergence of

renoprotective pharmacological therapies, such as renin-angiotensin-aldosterone system

(RAAS) inhibitors, sodium-glucose co-transporter-2 (SGLT2) inhibitors, and statins, has

enabled primary care clinicians to modify the risk of CKD progression, cardiovascular disease

(CVD), and mortality at an earlier stage [16]. As a result, risk factor modification and the

application of guideline-based therapy are increasingly being implemented in primary care

settings before referral to nephrology [4]. The focus has shifted from simply managing eGFR

thresholds to a more holistic approach that includes blood pressure control, optimising

glycaemic management in diabetes, and the use of agents that offer renoprotection [17, 18].

Given this evolution in CKD care, the question arises: does the timing of referral to nephrology

clinics still matter as a determinant of outcomes, particularly death following the initiation of

KRT? To address this, we conducted a retrospective analysis of participants enrolled in the

Chronic Kidney Disease Queensland Registry (CKD.QLD) to evaluate whether late referral

continues to impact outcomes in patients who progressed to KRT. Additionally, the study seeks

to critically evaluate and potentially refine the current operational definition of late referral

from primary care to nephrology services.

# Methods

## Data source and methods of data collection

The Chronic Kidney Disease in Queensland (CKD.QLD) was established as a collaborative of

most public sector kidney care practices in Queensland in May 2011. The CKD.QLD data

collection methods have been described by Venuthurapalli *et al*, briefly however, the main

objective of the registry was to profile participants with CKD, promoting CKD surveillance,

practice improvement and research within the kidney care practice network in the public health

system in QLD [19]. Data linkage framework was used to centralise data captured by multiple

mechanisms to an individual participant via a unique identifier. This enabled further

characterisation of participants with CKD, providing a comprehensive view of the health

services utilisation and costs and outcomes of people with CKD.

Adult participants aged 18 years and above with the diagnosis of CKD presenting to public

ambulatory nephrology clinics in the QLD health (QH) system were consented to have their

demographic and clinical data collected. More than 7,600 participants consented to be part of

the Registry between June 2011 and June 2018. Excluded were patients on kidney replacement

therapy (KRT) and those with acute kidney injury (AKI) unless they subsequently developed

and met the diagnostic criteria for CKD. Participants were followed until the start of KRT,

death or 30 June 2018. For the current study, we excluded participants whose date of referral

to the nephrology clinic couldn't be established.

The demographic variables recorded included age, gender, ethnicity and geographical location,

identified by postcode, as well as laboratory and clinical variables and outcome measures.

Variables of interest which were not already in the database were manually collected from

integrated electronic Medical Record (ieMR), the  Hospital Based Corporate Information

System (HBCIS), other QLD health platforms, and from private pathology laboratories as

appropriate, following granting of a Public Health Act (PHA) approval. Where only urine

protein-to-creatinine ratio (PCR) and dipstick protein were available, the equations developed

by Sumida et al were employed to calculate the predicted urine albumin-to-creatinine ratio

(UACR)[20]. The eGFR was calculated from serum creatinine using the Chronic Kidney

Disease Epidemiology Collaboration (CKD-EPI) equation). Data extraction was undertaken

between 18 January 2021 and 15 June 2025 in compliance with ethics and PHA approvals.

## Study design and population

132  This retrospective cohort study utilised data from participants aged ≥18 years enrolled in the

133  CKD.QLD Registry between 1 May 2011 and 30 June 2018 from seven public healthcare

134  nephrology clinics. A description of participants and basic study outcomes were previously

135  detailed in a published protocol [21].

## Outcomes and variables

Primary outcomes included progression to end-stage kidney disease (ESKD), commencement

of KRT, and mortality before and after commencement of KRT. Demographic and clinical

variables were investigated for their potential role as predictors or covariates of these outcomes.

Referral timing to nephrology services was assessed and defined by the conventional method

as the interval between the first encounter with the nephrology service and commencement of

KRT. Late referral was defined as commencing KRT within 12 months of the first visit to the

nephrology clinic, amongst those who progressed to KRT.

The kidney failure risk equation (KFRE) was applied to participants with CKD stages G3 to

G5 at the time of referral and available urine albumin-to-creatinine ratio (UACR) data to

calculate the risk of progression to KRT. Socio-Economic Indexes for Areas (SEIFA) Relative

Socio-economic Disadvantage (IRSD) scores as produced by the Australian Bureau of

Statistics were used to measure socioeconomic status of the enrolled participants by their

residential postcode [22]. The IRSD deciles were regrouped into quintiles (lowest, low, middle,

high, and highest) with the highest quintile representing the least disadvantaged postal areas

and the lowest quintile representing the most disadvantaged postal areas [23]. Participants were

further categorised into 3 levels of socio-economic status by combining the two lowest quintiles

into the low socio-economic status group, the two highest quintiles into the high socio-economic

status group, and the middle quintile into the middle socio-economic status group. Participants

with a recorded BMI were divided into obese (BMI $\geq$30) and non-obese (BMI <30).

Comorbidity burden was dichotomised into low (0 to 2 comorbidities) and high (3 or more

comorbidities).

## Data Analysis

Descriptive statistics and basic inferential statistics were employed to summarise demographic

and clinical characteristics, exploring basic data patterns and describing referral patterns.

Categorical variables were presented as proportions (numbers and percentages) and continuous

variables as means with standard deviations. Associations between time of referral and the

outcomes of death and KRT initiation were explored using a Cox proportional hazards

regression model. The initial multivariable model assessed the rate of mortality against the

following predictors: age at referral, eGFR at referral, gender, indigenous status,

socioeconomic status, primary renal disease (PRD), comorbidity score, and the comorbidities

of DM, CVD, hypertension, coronary artery disease (CAD), and the timing of referral presented

as late referral. The final model excluded variables with little univariate significance, (p-value

of >0.2) and summarized hazard ratios (HR) and 95% confidence intervals (95% CIs). The

Log-rank test was used to compare the difference of survival by referral groups, and the

Kaplan-Meier survival curve was used to depict the survival differences between the late and

early referred groups after KRT initiation. All analyses used STATA version 18 and $p < 0.05$

as the threshold for statistical significance.

## Ethical considerations

Approval for the study was granted by the Ethics Committee of the Royal Brisbane and

Women's Hospital in January 2021 (LNR/2020/QRBW/69707 14/01/2021). The requirement

for individual consent was waived as all patients had consented for the use of their data for the

purpose of research on recruitment into CKD.QLD Registry. Additionally, a Public Health Act

approval (QCOS/029817/ RD006802) was granted in August 2023 for the release of missing

patient data held by the contributing Queensland Health Hospital and Health Services.

## Results

### Study sample characteristics

Figure 1 outlines the participant selection process. A total of 3,775 participants were included

in the final analysis with median age of 65 years (mean 62.5).  Of these, 2,068 (54.8%) were

male and 327 (8.7%) identified as Indigenous Australians (Table 1).

Socioeconomic status, as measured by the IRSD, revealed that a significant portion of the

participants (1,806, 47.8%) lived in the most disadvantaged postal areas (low socioeconomic

status) (Table 1).  This group represented the largest proportion of participants across all stages

of CKD (Table 1).

At the time of referral, nearly half of the participants, 1,872 (49.6%) were in stage G3 CKD

(G3A and G3B), whereas 713 (18.9%) were in stages 1 or 2 (eGFR of $\geq$60ml/min/1.73m$^2$).

CKD stages G4 and 5 accounted for 1,190 (31.5%) participants, predominately G4 (Table 1).

UACR data were available for 2,605 (69%) participants, with 920 (35.3%) exhibiting a UACR

of $\geq$ 30mg/mmol (Table S1).

There were 17 types of comorbidities recorded, with the number of comorbidities ranging from

0 to 15 per participant. A high proportion met the high comorbidity score criteria (range 63%-

70%) in all stages of CKD (Table 1). There were twice as many participants in the high

comorbidity group (67.6%) of whom 1,737 (68.1%) had an eGFR of $\geq$30 ml/min at the time of

referral (Table S2). Hypertension was the most common comorbidity, present in 77.5% of

participants, followed by DM and cardiovascular disease (CVD), 44.9% and 40.7%

respectively (Table 1).

## Referral thresholds and outcomes

Around one third of participants (1,194, 31.6%) fulfilled the KHA eGFR threshold

(<30ml/min) for specialist referral (Table S2). Among the 2,581 (68.4%) who did not fulfill

the eGFR threshold, 216 (8.4%) progressed to KRT while 331 (12.8%) died without KRT

(Table S2). Similarly, though 1,685 (64.7%) participants did not fulfil the UACR threshold of

$\geq$30 mg/mmol for referral, of these 191 (11.3%) progressed to KRT while 221 (13.1%) died

without KRT (Table S1).

Of the 2,605 participants with both eGFR and UACR data, 371 (14.2%) met both referral

criteria, of which 150 (40.4%) subsequently requiring KRT (Table S3). Conversely, 1,203

(46.2%) did not meet either threshold for referral, yet 79 (6.6%) of these went on to require

KRT at some point during the period of follow up (Table S3).

## Mortality and progression to ESKD

During the follow up period, 722 (19.1%) participants died, with the majority (598, 82.8%)

dying prior to commencing KRT, while 775 (21%) participants progressed to ESKD, of whom

513 (66.2%) received KRT (Table 1). Nearly half of all deaths (356, 49.3%) occurred among

participants from the low socioeconomic status group (Figure 2).

The Cox proportional hazards regression model indicated that participants who had been under

nephrology care for less than 12 months before starting KRT (late referral) had a 54% lower

hazard rate of mortality compared to those who had received care for more than 12 months

(HR <12 months, 0.46; 95% CI, 0.27 to 0.79; p = 0.01) (Table 2). The Log-rank test showed a

statistically significant difference in survival between the referral groups (p = 0.002) (Table

S4). The Kaplan-Meier survival curve shows longer survival after KRT initiation in the late

referred group (Figure 3). Advancing age was associated with increased mortality rate, with

each 5-year increment corresponding to a 15% increase in the hazard of death (HR = 1.15).

Additionally, the presence of cardiovascular disease was associated with a nearly twofold

increase in mortality rate (HR = 1.90) (Table 2).

## Referral timing and comorbidity

229 Of the 513 participants who commenced KRT, 60 (11.7%) were classified as late referrals.

230 Among these, 32 (53.3%) were from low socioeconomic group, compared to 20 (33.3%) from

231 high socioeconomic group (Table 3).

232 Most participants who started KRT (397, 77.4%) and most who died (473, 65.5%) were in the

233 high comorbidity group (Table 2). Of those who died after starting KRT, (101, 81.5%) were

from the high comorbidity group, most of whom (351, 88.4%) had been referred early (Table S5). Only 15 (12.1%) of those who died post-KRT were late referrals, with 3 (20%) of these dying in the first 12 months of starting KRT (Table 3). These findings suggest that comorbidity burden rather than late referral is a more robust predictor of death.

## CKD stage and risk of progression

Participants in CKD stages 1 to 3 were found to be at greater risk of death before KRT than progress to KRT (55.4% vs 43.5%), whereas those in stages 4 & 5 were more likely to initiate KRT than die before KRT (56.5% vs 44.6%) (Table 1). Overall, mortality rates increased with advancing CKD stages (Figure S1)

## KFRE application and predictive accuracy

Among the 1,743 participants who did not fulfil the KHA eGFR criteria for referral and whose UACR was available, application of the 5-year KFRE at 3% & 5% thresholds identified 708 (40.6%) and 509 (29.2%) as high risk, respectively. Of these, 144 (20.3%) and 126 (24.8%) progressed to KRT, while 91 (12.9%) and 65 (12.8%) died without KRT (Table S6).

When applied to participants who met the KHA eGFR referral threshold, the KFRE at both 3% and 5% thresholds, demonstrated similar predictive accuracy for KRT progression (99.6% and 96.6% respectively). The observed risks for KRT and death were also similar (KRT:31.0% and 31.9%; death:15.6% and 14.9% (Table S7).

These findings suggest that the eGFR threshold alone is as effective as the 5-year KFRE in identifying individuals at risk of progressing to KRT as well as those who died without KRT. However, the KFRE enabled identification of additional high-risk participants who would otherwise be missed using the eGFR criteria alone.

**Table 1 Baseline characteristics at the time of referral and outcomes**

| Characteristics | Total sample | Stage 1 | Stage 2 | Stage 3A | Stage 3B | Stage 4 | Stage 5 |
|---|---|---|---|---|---|---|---|
| Participants, n (%) | 3775 | 7.9% | 11.0% | 18.6% | 31.0% | 26.2% | 5.3% |
| **Demographics** | | | | | | | |
| Age, mean | 62.5 | 48.2 | 57.6 | 62.5 | 65.3 | 65.1 | 64.3 |
| Gender, male n (%) | 2,069 (54.8) | 46.1 | 56.0 | 57.8 | 52.6 | 56.5 | 58.8 |
| Indigenous, n (%) | 327 | 32 | 49 | 52 | 86 | 89 | 19 |
| **SES Status** | | | | | | | |
| Low status n (%) | 1806 (47.8) | 48.2 | 52.2 | 49.9 | 47.4 | 45.4 | 45.7 |
| Middle status n (%) | 1006 (26.7) | 25.9 | 24.5 | 25.6 | 26.8 | 28.1 | 28.1 |
| High status n (%) | 963 (25.5) | 25.9 | 23.3 | 24.5 | 25.8 | 26.5 | 26.1 |
| BMI, n (mean) | 2500 (31.7) | 31.6 | 32.2 | 31.5 | 31.9 | 31.6 | 30.9 |
| **Primary Renal disease** | | | | | | | |
| DN, n (%) | 1,066 (28.2) | 27.6 | 30.8 | 29.9 | 26.9 | 27.8 | 28.6 |
| GN, n (%) | 473 (12.5) | 12.5 | 12.0 | 11.4 | 13.2 | 12.5 | 14.1 |
| GRD, n (%) | 183 (4.9) | 3.7 | 12.0 | 4.3 | 5.4 | 5.2 | 4.5 |
| RV, n (%) | 985 (26.1) | 23.9 | 28.4 | 28.6 | 27.0 | 23.1 | 25.6 |
| UNC, n (%) | 403 (10.7) | 10.8 | 8.4 | 9.8 | 11.4 | 12.2 | 6.5 |
| Other, n (%) | 665 (17.6) | 21.6 | 15.9 | 16.1 | 16.3 | 19.3 | 20.6 |
| **Comorbidities** | | | | | | | |
| DM, n (%) | 1,694 (44.9) | 32.0 | 42.8 | 46.0 | 47.1 | 46.3 | 44.2 |
| HTN, n (%) | 2,926 (77.5) | 77.7 | 76.7 | 74.8 | 77.4 | 80.7 | 78.9 |
| CVD, n (%) | 1,538 (40.7) | 21.2 | 32.2 | 41.1 | 43.4 | 47.4 | 37.7 |
| CAD, n (%) | 886 (23.5) | 16.8 | 19.2 | 23.3 | 25.0 | 26.1 | 23.5 |
| Obesity, n (%) | 1,366 (54.6) | 51.2 | 56.6 | 53.5 | 56.9 | 54.0 | 49.1 |
| **Comorbidity Score** | | | | | | | |
| Low comorbidity, n (%) | 1223 (32.4) | 34.0 | 33.2 | 37.1 | 29.8 | 32.0 | 32.4 |
| High comorbidity, n (%) | 2552 (67.6) | 66.0 | 66.8 | 62.9 | 70.2 | 68.0 | 67.6 |
| **Laboratory Parameters** | | | | | | | |
| eGFR, mean | 42.4 | 90 | 71.5 | 51.0 | 36.7 | 22.9 | 11.4 |
| UACR, mean | 56.1 | 44.2 | 68.5 | 48.6 | 44.5 | 66.5 | 86.8 |
| **Outcomes** | | | | | | | |
| ESKD, n (%) | 775 (20.5) | 5.7 | 11.8 | 12.4 | 16.4 | 34.4 | 54.8 |
| KRT, n (%) | 513 (13.6) | 3.7 | 8.4 | 8.8 | 10.6 | 23.4 | 34.7 |
| Total death, n (%) | 722 (19.1) | 5.7 | 10.6 | 15.1 | 18.2 | 27.1 | 36.7 |
| Death without KRT, n (%) | 598 (15.8) | 5.7 | 10.1 | 12.7 | 15.7 | 21.1 | 29.2 |

*SD: standard deviation; BMI: body mass index; DN: diabetic nephropathy; GN: glomerulonephritis;*

*GRD: genetic renal disease; RV: renovascular disease; UNC: unknown cause; DM: diabetes mellitus;*

*HTN: hypertension; CVD: cardiovascular disease; CAD: coronary artery disease; eGFR: estimated*

*glomerular filtration rate; UACR: urine albumin-to-creatinine ratio; ESKD: end-stage kidney disease;*

*KRT: kidney replacement therapy*

**Table 2.** Final Cox regression model

| Predictor | Hazard ratio | [95% CI] | p-value |
|---|---|---|---|
| Age at referral | 1.15 | 1.07 – 1.24 | <0.01 |
| Cardiovascular Disease | 1.9 | 1.31 – 2.75 | <0.01 |
| Late referral | 0.46 | 0.27 – 0.79 | 0.01 |

*CI: confidence interval*

**Table 3** Characteristics of participants who progressed to KRT

| | Total<br>N = 513 | Early Referral<br>N = 453 | Late Referral<br>N = 60 |
|---|---|---|---|
| **Parameters at time of referral** | | | |
| **Age (mean, SD)** | 56.1 ± 13.9 | 56.1 ± 13.8 | 56.2 ± 15.2 |
| **Gender (male) n (%)** | 317 (61.8) | 276 (60.9) | 41 (68.3) |
| **Indigenous, n (%)** | 76 (14.8) | 69 (15.2) | 7 (11.7) |
| **Social status** | | | |
| **Low status, n (%)** | 261 (50.9) | 229 (50.6) | 32 (53.3) |
| **Middle status, n (%)** | 107 (20.9) | 99 (21.9) | 8 (13.3) |
| **High status, n (%)** | 145 (28.3) | 125 (27.6) | 20 (33.3) |
| **BMI Category** | | | |
| **<30, n (%)** | 127 (45.2) | 105 (43.0) | 22 (59.5) |
| **≥30, n (%)** | 154 (54.8) | 139 (57.0) | 15 (40.5) |
| **Primary Renal disease** | | | |
| **DN, n (%)** | 196 (38.2) | 169 (37.3) | 27 (45) |
| **GN, n (%)** | 83 (16.2) | 71 (15.7) | 12 (20) |
| **GRD, n (%)** | 51 (9.9) | 46 (10.2) | 5 (8.3) |
| **RV, n (%)** | 90 (17.5) | 81 (17.9) | 9 (15.0) |
| **UNC, n (%)** | 24 (4.68) | 23 (5.1) | 1 (1.7) |
| **Other, n (%)** | 69 (13.5) | 63 (13.9) | 6 (10) |
| **Comorbidities** | | | |
| **DM, n (%)** | 166 (32.4) | 144 (31.8) | 22 (36.7) |
| **HTN, n (%)** | 435 (84.8) | 390 (86.1) | 45 (75) |
| **CVD, n (%)** | 278 (54.2) | 247 (54.5) | 31 (51.7) |
| **CAD, n (%)** | 151 (29.4) | 138 (30.5) | 13 (21.7) |
| **Comorbidity Score** | | | |
| **Low Comorbidity, n (%)** | 116 (22.6) | 102 (22.50) | 14 (23.3) |
| **High Comorbidity, n (%)** | 397 (77.4) | 351 (77.5) | 46 (76.7) |
| **Death after KRT, n (%)** | 124 (24.2) | 109 (24.1) | 15 (25.0) |
| **Within 12 months, n (%)** | 26 (21.0) | 23 (21.1) | 3 (20.0) |
| **≥12 months < 24 months, n (%)** | 30 (24.2) | 28 (25.7) | 2 (13.3) |
| **≥ 24 months, n (%)** | 68 (54.8) | 58 (53.2) | 10 (66.7) |
| **Laboratory Parameters** | | | |
| **eGFR (mean, SD)** | 31.0 ± 17.6 | 31.9 ± 17.6 | 24.3 ± 16.2 |
| **UACR (mean, SD)** | 102.8 ± 145.4 | 102.0 (145.7) | 109 (144.0) |
| **Risk Classification** | | | |
| **eGFR < 30, n (%)** | 297 (57.9) | 253 (55.9) | 44 (73.3) |
| **eGFR ≥ 30, n (%)** | 216 (42.1) | 200 (44.2) | 16 (26.7) |
| **UACR < 30, n (%)** | 191 (41.5) | 171 (41.9) | 20 (38.5) |
| **UACR ≥ 30, n (%)** | 269 (58.5) | 237 (58.1) | 32 (61.5) |
| **5-Year KFRE < 5, n (%)** | 73 (15.9) | 66 (16.2) | 7 (13.5) |
| **5-Year KFRE ≥ 5, n (%)** | 387 (84.1) | 342 (83.8) | 45 (86.5) |

*SD: standard deviation; BMI: body mass index; DN: diabetic nephropathy; GN: glomerulonephritis;*

*GRD: genetic renal disease; RV: renovascular disease; UNC: unknown cause; DM: diabetes mellitus;*

*HTN: hypertension; CVD: cardiovascular disease; CAD: coronary artery disease; eGFR: estimated*

*glomerular filtration rate; UACR: urine albumin-to-creatinine ratio; ESKD: end-stage kidney disease;*

*KFRE: kidney failure risk equation*

# Discussion

In our study, we found that participants who were in the care of nephrology clinics for more than 12 months before commencing KRT (i.e. usually considered 'timely' referral) exhibited lower survival rates than those who were referred within 12 months of KRT initiation (i.e., 'late' referral). This finding contrasts with prior studies that have reported poorer survival rates in those patients referred late using the same 12-month threshold. Previous studies have found that late referral is associated with increased mortality and poorer outcomes after starting KRT [10, 11]. The presumed benefits of early referral included better preparation for dialysis or transplantation, timely management of complications, and improved patient education. However, these studies often predate the widespread adoption of contemporary CKD management strategies [12, 24].

These results suggest that the duration of nephrology care alone may not be a sufficient explanatory factor for survival after initiation of KRT. Previous research has highlighted that even patients who have been under nephrology care for longer periods may still undergo urgent start dialysis [25-27]. Moreover, nephrology care does not always ensure optimal dialysis preparation. For example, Hamadahet al. [28] found that only 30.8% of patients under nephrology care for more than 12 months started haemodialysis with an arteriovenous fistula (AVF) . Similarly, Mendelssohnet al. [29] demonstrated that many patients who were followed by a nephrologist experienced suboptimal dialysis commencement, defined as using a temporary central dialysis catheter access for haemodialysis or peritoneal dialysis immediately after placement of a PD catheter. A follow-up study by the same group replicated the results of their study by demonstrating a 56.4% rate of suboptimal starts in early referred patients [30].

Commencing dialysis with a temporary catheter has often been cited as a key reason why patients fare poorly after starting dialysis [31]. In our analysis, we chose the 12-months cut-off

to define late referral to eliminate vascular access as a potential cause of poor outcomes after

starting dialysis, arguing that 12 months would be long enough for the nephrology clinics to

facilitate the creation of permanent vascular access before the start of dialysis. While it can be

argued that timing of referral alone (i.e., duration of pre-dialysis care) cannot be sufficient to

account for the superior outcomes observed in early referred patients, it is also instructive to

acknowledge that a longer duration of pre-dialysis care creates opportunities for an increased

number of visits to the nephrology clinics and allows for more time for effective treatment and

correction of anaemia and other complications of CKD, hence likely lowering the risk of death.

Moreover, frequent visits to the nephrology clinic and early exposure to multidisciplinary care

clinics have been demonstrated to lead to timely dialysis initiation. Early exposure allows

adequate and comprehensive predialysis education which in turn promotes supported modality

selection and timely permanent access creation [32, 33].

We observed a high burden of comorbidities in all participants, most of whom had an eGFR of

≥30 ml/min at the time of referral. This trend was maintained in participants who progressed

to KRT; a higher burden of comorbidities was observed in those who were referred early

(commenced KRT after 12 months of referral) and in those who died after commencing KRT.

These results suggest that participants who had more comorbid conditions were more readily

referred early to nephrology practice rather than stable patients, whose main reason of referral

would have been uncomplicated CKD. Preexisting comorbidities have been reported to predict

higher mortality rates in patients starting dialysis [34]. In a prospective cohort study of patients

with CKD stage G5 and delayed initiation of haemodialysis, patients with a high and very high

Charlson Comorbidity Index (CCI) were found to have an increased risk for all-cause mortality,

with mortality risk increasing progressively as the CCI score increased [35]. High comorbidity

rate therefore appears to have been the major determinant of mortality after KRT initiation,

superseding the impact of late referral to nephrology services, which in our study did not predict mortality.

Low socioeconomic status was a key characteristic observed in all stages of CKD and was also a predictor of both progression to ESKD and mortality before and after initiation of KRT. Studies have previously demonstrated low socioeconomic status to be a significant risk factor for CKD progression and mortality, leading to higher rates of CVD and kidney failure, and ultimately, increased all-cause mortality [36]. Factors that have been identified as drivers of CKD progression and death in individuals from low socioeconomic background include delayed diagnosis due to poor access to healthcare, unfavourable living conditions, poor nutrition, and higher burden of chronic diseases [37].

On assessing compliance with the KHA referral criteria, we observed that 46.3% of participants whose UACR was available did not fulfill either the eGFR or UACR thresholds for referral, which means that they would have been either referred for reasons other than the eGFR or UACR thresholds, or they may have been referred inappropriately and hence could have been managed in primary care. In a similar retrospective cohort study of CKD patients over 14 years, Ghimireet al. [38] observed guideline discordant rate of 59% and concluded that many of the referred patients being seen by nephrologists might have had mild CKD that could have been safely managed in primary care. Singhet al. [39] reported that adherence to the KDIGO guidelines would result in a supply-demand mismatch and concluded that implementing the guidelines may not be feasible. Kielet al. [40] came to a similar conclusion, reporting that implementing KDIGO criteria would lead to more than double increase in referral rate compared to actual referral. It has therefore been long argued that most current referral criteria are not designed to accurately distinguish between high and low risk patients. In our study, we observed that a significant proportion of participants who did not fulfill the KHA eGFR threshold for referral were deemed high risk when the 5-year KFRE was applied at both the

3% and 5% thresholds. Additionally, when applied to participants who did not fulfill the eGFR

threshold for referral, the 5-year KFRE better identified participants who progressed to KRT

than who died.

The period when the participants in our study were followed up in CKD.QLD Registry in

relation to worldwide kidney care practice patterns is important. Substantial improvements in

the management of CKD in primary care settings may explain our study's differing results.

Enhanced education of primary care providers, improved disease definition and staging, and

the integration of guideline-based therapies have collectively contributed to better patient

outcomes. The widespread use of new pharmacological agents, particularly those with proven

renoprotective and cardioprotective effects, has further lessened the reliance on specialist

referral for optimal care.

These results suggest that we might be seeing the impact of improved CKD care in terms of

early detection and timely intervention within primary care to mitigate the risk of late referral.

With the advent of therapies capable of delaying the need for dialysis by decades, the necessity

for routine referral based solely on eGFR thresholds or arbitrary timing will need to be

reevaluated. Referral to nephrology may be best reserved for high-risk patients, identified

through validated risk prediction models like the KFRE, or those with complex needs such as

glomerulonephritis, vasculitis, genetic kidney diseases, or advanced CKD (stages G4 and G5)

requiring specialised interventions (e.g., phosphate binders, erythropoiesis-stimulating agents,

or preparation for KRT). Most patients referred to nephrology clinics are already receiving

optimised medical therapy, making the incremental benefit of specialist care less pronounced

in the early stages of CKD.

One of the key strengths of our study is that it includes important baseline characteristics of

participants at the time they were referred, unlike many existing studies on CKD referral

patterns that focus only on patient data at the start of KRT. Additionally, we were able to

calculate the UACR for a substantial number of participants, which allowed us to use the KFRE

to compare predicted outcomes with actual results. However, the retrospective nature of the

study meant that some clinical and laboratory data were missing from the Registry, limiting

the depth of our analysis. Other limitations included being unable to determine the reasons for

referral to nephrology clinics, making it difficult to assess whether participants who didn't meet

the eGFR and UACR criteria were referred appropriately. Furthermore, the Registry did not

record the type of vascular access used at the start of KRT, preventing us from evaluating its

potential effect on post-KRT mortality.

## 381 The case for a new definition of late referral: A risk-based 382 approach

We propose that risk stratification be incorporated into the definition of the timeliness of

referral of individuals with CKD from primary care to specialist nephrology services, and that

the definition be applicable at the point of initial nephrology consultation. This prospective

approach will enable timely interventions to mitigate adverse outcomes. The current

retrospective definition, based on variable intervals between the first nephrology visit and

initiation of KRT, lacks universal agreement, with timeframes ranging from 1 to 12 months.

This lack of a universally accepted time interval has compromised the integrity of systematic

reviews which have been conducted on the topic due to the heterogeneity of the time frames

used in the many retrospective cohort studies available in the literature. Moreover,

retrospective definitions offer little guidance to primary care physicians seeking optimal

referral timing, nor do they assist nephrologists in assessing referral appropriateness at the time

of the first clinic visit. Having this knowledge upfront will enable clinicians to streamline their

delivery of care and resources according to specific goals of care, that is, whether initiating

KRT preparation or focusing on slowing CKD progression and reducing cardiovascular risk

and death.

# Conclusions

Our analysis shows that the rate of late referral in our sample was lower than the rates that have

been reported in previous studies, suggesting that in the current era of enhanced CKD

management at the primary care level, the timing of referral to nephrology services is no longer

a significant determinant of post-KRT mortality. Instead, high comorbidity burden and low

social status seemed to be stronger predictors of mortality after KRT initiation. Other results

found that the accuracy of the KHA eGFR threshold of <30ml/min was comparable to the

KFRE 5-year risk of 3% and 5% in identifying participants who required KRT or died,

however, it missed a significant proportion of high-risk participants who later progressed to

KRT and death.

We conclude that the timing of referral may no longer be reliable in determining outcomes for

patients with CKD, given the advancements in primary care management and the availability

of effective renoprotective therapies and suggest that efforts be made to develop a more

universally accepted definition of late referral of patients with CKD from primary care to

specialist nephrology that incorporates risk stratification. We also encourage the empowering

of the primary care with targeted education programs with emphasis on guideline adherence

and incorporation of renoprotective agents at primary care level so that referral to secondary

care can be reduced.

## Author Declaration

The authors declare no competing interests.

## Author contributions

**Conceptualization**: Clyson Mutatiri, Sree Krishna Venuthurupalli, Srinivas Kondalsamy-Chennakesavan, Angela Ratsch, and Matthew McGrail.

**Methodology**: Clyson Mutatiri, Sree Krishna Venuthurupalli, Angela Ratsch Srinivas Kondalsamy-Chennakesavan, Matthew McGrail.

**Writing - original draft preparation**: Clyson Mutatiri, Matthew McGrail, Srinivas Kondalsamy-Chennakesavan, Angela Ratsch, Sree Krishna Venuthurupalli.

**Writing - review and editing**: Clyson Mutatiri, Matthew McGrail, Angela Ratsch, Srinivas Kondalsamy-Chennakesavan, Sree Krishna Venuthurupalli.

## Funding

None of the authors received any funding for their contribution to the development of this manuscript.

## Acknowledgments

We would like to thank the CKD.QLD Registry for granting us the approval of access to CKD.QLD Registry Patient Data and support for the progression of this research. We would also like to acknowledge the "in-kind" support provided by Wide Bay Hospital and Health Service to the researchers and for relevant resources including computers, telephone, and office space for the duration of this project. This study was partly supported by the Australian Government Department of Health under the Rural Health Multidisciplinary Training Programme.

# References

1. Lv JC, Zhang LX. Prevalence and Disease Burden of Chronic Kidney Disease. Adv Exp Med Biol. 2019;1165:3-15.doi: 10.1007/978-981-13-8871-2_1

2. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl (2011). 2022;12(1):7-11.doi: 10.1016/j.kisu.2021.11.003

3. Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat Rev Nephrol. 2024;20(7):473-85.doi: 10.1038/s41581-024-00820-6

4. Kushner P, Khunti K, Cebrian A, Deed G. Early identification and management of chronic kidney disease: anarrative review of the crucial role of primary care practitioners. Adv Ther. 2024;41(10):3757-70.doi: 10.1007/s12325-024-02957-z

5. Samal L, Wright A, Waikar SS, Linder JA. Nephrology co-management versus primary care solo management for early chronic kidney disease: a retrospective cross-sectional analysis. BMC Nephrol. 2015;16(1):162.doi: 10.1186/s12882-015-0154-x

6. Wright J, Glenister KM, Thwaites R, Terry D. The importance of adequate referrals for chronic kidney disease management in a regional Australian area of nephrologist workforce shortage. Aust J Gen Pract. 2018;47(1/2):58-62.doi: 10.3316/informit.462183610095113

7. KDIGO. Clinical practice guideline for the evaluation and management of chronic kideny disease. Kidney Disease Kid Int. 2012;3(1).doi:

8. Kidney Health Australia. Kidney Health Australia;  [Available from: https://kidney.org.au/health-professionals#:~:text=We%20are%20a%20trusted%20source,waste%20product)%20in%20your%20blood.

9.    Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic

kidney disease: a systematic review. Am J Med. 2011;124(11):1073-80 e2.doi:

10.1016/j.amjmed.2011.04.026

10.   Dhanorkar M, Prasad N, Kushwaha R, Behera M, Bhaduaria D, Yaccha M, et al.

Impact of early versus late referral to nephrologists on outcomes of chronic kidney

disease patients in northern India. Int J Nephrol. 2022;2022:4768540.doi:

10.1155/2022/4768540

11.   Kim DH, Kim M, Kim H, Kim YL, Kang SW, Yang CW, et al. Early referral to a

nephrologist improved patient survival: prospective cohort study for end-stage renal

disease in Korea. PloS ONE. 2013;8(1):e55323.doi: 10.1371/journal.pone.0055323

12.   Obrador GT, Pereira BJ. Early referral to the nephrologist and timely initiation of

renal replacement therapy: a paradigm shift in the management of patients with

chronic renal failure. Am J Kidney Dis. 1998;31(3):398-417.doi:

10.1053/ajkd.1998.v31.pm9506677

13.   Iwata Y, Okushima H, Takatsuka T, Yoshimura D, Kawamura T, Iio R, et al.

Duration of predialysis nephrological care and mortality after dialysis initiation. Clin

Exp Nephrol. 2020;24(8):705-14.doi: 10.1007/s10157-020-01889-6

14.   Australian Institute of Health and Welfare. Chronic kidney disease: Australian facts,.

Canberra: AIHW; 2024 12 Dec 2024.

15.   Beernink JM, van Mil D, Laverman GD, Heerspink HJL, Gansevoort RT.

Developments in albuminuria testing: a key biomarker for detection, prognosis and

surveillance of kidney and cardiovascular disease-A practical update for clinicians.

Diabetes Obes Metab. 2025;27 Suppl 8(Suppl 8):15-33.doi: 10.1111/dom.16359

16.   Cortinovis M, Perico N, Remuzzi G. Innovative therapeutics for renoprotection:

where we are. Pharmacol Rev. 2025:100060.doi: 10.1016/j.pharmr.2025.100060

17.    Elendu C, Elendu RC, Enyong JM, Ibhiedu JO, Ishola IV, Egbunu EO, et al.

Comprehensive review of current management guidelines of chronic kidney disease.

Medicine (Baltimore). 2023;102(23):e33984.doi: 10.1097/MD.000000000033984

18.    Wehbe F, Elliott M, Levin A. Chronic kidney diseases at the crossroads: From

failures to future therapies. Kidney Int Rep [Internet]. 2025; Octboer 2025.doi:

10.1016/j.ekir.2025.09.050

19.    Venuthurupalli SK, Hoy WE, Healy HG, Cameron A, Fassett RG. CKD.QLD:

establishment of a chronic kidney disease [CKD] registry in Queensland, Australia.

BMC Nephrol. 2017;18(1):189.doi: 10.1186/s12882-017-0607-5

20.    Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, et al. Conversion

of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine

ratio for use in chronic kidney disease screening and prognosis: an individual

participant-based meta-analysis. Ann Intern Med. 2020;173(6):426-35.doi:

10.7326/M20-0529

21.    Mutatiri C, Ratsch A, McGrail MR, Venuthurupalli S, Kondalsamy Chennakesavan S.

Referral patterns, disease progression and impact of the kidney failure risk equation

(KFRE) in a Queensland Chronic Kidney Disease Registry (CKD.QLD) cohort: a

study protocol. BMJ Open. 2022;12(2):e052790.doi: 10.1136/bmjopen-2021-052790

22.    Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational

assessment of accuracy of equations for predicting risk of kidney failure: a meta-

analysis. JAMA. 2016;315(2):164-74.doi: 10.1001/jama.2015.18202

23.    Australian Bureau of Statistics. Socio-economic indexes for areas (SEIFA), Australia:

Australian Bureau of Statistics; 2021 [Available from:

https://www.abs.gov.au/statistics/people/people-and-communities/socio-economic-

indexes-areas-seifa-australia/latest-release.

24.  Lhotta K, Zoebl M, Mayer G, Kronenberg F. Late referral defined by renal function:

association with morbidity and mortality. J Nephrol. 2003;16(6):855-61.doi:

25.  Crews DC, Jaar BG, Plantinga LC, Kassem HS, Fink NE, Powe NR. Inpatient

hemodialysis initiation: reasons, risk factors and outcomes. Nephron Clin Pract.

2010;114(1):c19-28.doi: 10.1159/000245066

26.  Marron B, Ortiz A, de Sequera P, Martin-Reyes G, de Arriba G, Lamas JM, et al.

Impact of end-stage renal disease care in planned dialysis start and type of renal

replacement therapy--a Spanish multicentre experience. Nephrol Dial Transplant.

2006;21 Suppl 2(suppl_2):ii51-5.doi: 10.1093/ndt/gfl191

27.  Buck J, Baker R, Cannaby A-M, Nicholson S, Peters J, Warwick G. Why do patients

known to renal services still undergo urgent dialysis initiation? AJ Nephrol cross-

sectional survey. Nephrol Dial Transplant. 2007;22(11):3240-5.doi:

10.1093/ndt/gfm387

28.  Hamadah AM, Gharaibeh K. Predialysis nephrology care and its impact on initial

vascular access type in hemodialysis patients in Jordan. Saudi J Kidney Dis Transpl.

2019;30(5):1103-10.doi: 10.4103/1319-2442.270266

29.  Mendelssohn DC, Curtis B, Yeates K, Langlois S, MacRae JM, Semeniuk LM, et al.

Suboptimal initiation of dialysis with and without early referral to a nephrologist.

Nephrol Dial Transplant. 2011;26(9):2959-65.doi: 10.1093/ndt/gfq843

30.  Hughes SA, Mendelssohn JG, Tobe SW, McFarlane PA, Mendelssohn DC. Factors

associated with suboptimal initiation of dialysis despite early nephrologist referral.

Nephrol Dial Transplant. 2013;28(2):392-7.doi: 10.1093/ndt/gfs431

31.  Avorn J, Winkelmayer WC, Bohn RL, Levin R, Glynn RJ, Levy E, et al. Delayed

nephrologist referral and inadequate vascular access in patients with advanced chronic

538           kidney failure. J Clin Epidemiol. 2002;55(7):711-6.doi: 10.1016/s0895-

539           4356(02)00415-8

540   32.   Heaf J, Heiro M, Petersons A, Vernere B, Povlsen JV, Sørensen AB, et al. Choice of

541           dialysis modality among patients initiating dialysis: results of the Peridialysis study.

542           Clin Kidney J. 2021;14(9):2064-74.doi: 10.1093/ckj/sfaa260

543   33.   Brown PA, Akbari A, Molnar AO, Taran S, Bissonnette J, Sood M, et al. Factors

544           associated with unplanned dialysis starts in patients followed by nephrologists: A

545           retropective cohort study. PloS ONE. 2015;10(6):e0130080.doi:

546           10.1371/journal.pone.0130080

547   34.   Chia JMX, Goh ZS, Seow PS, Seow TY, Choo JCJ, Foo MW, et al. Psychosocial

548           factors, intentions to pursue arteriovenous sialysis access, and access outcomes: a

549           cohort study. Am J Kidney Dis. 2021;77(6):931-40.doi: 10.1053/j.ajkd.2020.09.019

550   35.   Flores-Mendoza AP, Garcia-Campa M, Sanchez-Martinez C, Guerrero-Gonzalez E,

551           Rizo-Topete LM, Olivo-Gutierrez MC. Charlson comorbidity index and all-cause

552           mortality in patients with delayed hemodialysis initiation: a prospective cohort study.

553           BMC Nephrol. 2025;26(1):376.doi: 10.1186/s12882-025-04197-x

554   36.   Tannor EK, Chika OU, Okpechi IG. The impact of low socioeconomic status on

555           progression of chronic kidney disease in low- and lower middle-income countries.

556           Semin Nephrol. 2022;42(5):151338.doi: 10.1016/j.semnephrol.2023.151338

557   37.   Crews DC, Novick TK. Social Determinants of CKD Hotspots. Semin Nephrol.

558           2019;39(3):256-62.doi: 10.1016/j.semnephrol.2019.02.003

559   38.   Ghimire A, Ye F, Hemmelgarn B, Zaidi D, Jindal KK, Tonelli MA, et al. Trends in

560           nephrology referral patterns for patients with chronic kidney disease: Retrospective

561           cohort study. PloS ONE. 2022;17(8):e0272689.doi: 10.1371/journal.pone.0272689

39.    Singh K, Waikar SS, Samal L. Evaluating the feasibility of the KDIGO CKD referral

recommendations. BMC Nephrol. 2017;18(1):223.doi: 10.1186/s12882-017-0646-y

40.    Kiel S, Weckmann G, Chenot JF, Stracke S, Spallek J, Angelow A. Referral criteria

for chronic kidney disease: implications for disease management and healthcare

expenditure-analysis of a population-based sample. BMC Nephrol.

2022;23(1):225.doi: 10.1186/s12882-022-02845-0

# 570 Supporting information

**S1Table** UACR categories

**S2 Table** eGFR categories

**S3 Table** KRT by eGFR and UACR categories

**S4 Table** Log-rank test for equality of survivor functions by referral status

**S5 Table** Comorbidity score by KRT death and referral status

**S1 Fig** Distribution of death without KRT by CKD stage

**S6 Table** Comparison of eGFR threshold and KFRE Subgroup of participants with eGFR of

≥30ml/min

**S7 Table** Comparison of eGFR threshold and KFRE Subgroup of participants with eGFR of

<30ml/min

Distribution of death without KRT by CKD st

Total number at risk

| | | | | | |
|---|---|---|---|---|---|
| Early referral (≥12 months) | 448 | 341 | 230 | 105 | 2 |
| Late referral (<12 months) | 60 | 52 | 43 | 32 | 0 |

Kaplan Meier survival curves after dialysis i

Comparison of total deaths by socioeconor

Flowchart of participant selection for inclus